---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-063510"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2026-09-25T13:11:02+00:00"
generated_at: "2026-10-12T13:19:47.946292+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.08
calibrated_materiality_score: 0.08
confidence: "low"
source: SEC EDGAR
---

# Vistagen files new September 2026 corporate presentation; no financial or clinical data in the text

## Summary
- Exhibit 99.1 is a corporate presentation dated September 2026 titled 'Harnessing the therapeutic power and potential of brain regulation with nose-to-brain neurocircuitry.'
- The appended exhibit contains only the title slide; no pipeline updates, trial results, cash balance, revenue or guidance figures were disclosed.
- Filing signed September 25, 2026 by President and CEO Shawn K. Singh; registrant is Vistagen Therapeutics, Inc., South San Francisco, California.
- No clinical, regulatory, financing or partnership event is described, so no directional read is possible from this filing.

## SEC filing metadata
- accession: 0001628280-26-063510
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2026-09-25T13:11:02+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.08
- calibrated_materiality_score: 0.08
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828026063510/0001628280-26-063510-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828026063510/vtgn-20260925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-063510
- JSON: https://secwatch.observer/filing/0001628280-26-063510.json
- Plain text: https://secwatch.observer/filing/0001628280-26-063510.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.